Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab)for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
百時美施貴寶（紐交所：BMY）今天宣佈，歐盟委員會（EC）已批准Opdivo（尼伏單抗）聯合Yervoy（伊匹木單抗）用於治療成人微衛星不穩定性高（MSI-H）或錯配修復缺陷（dMMR）不可手術切除或轉移性結直腸癌（mCRC）的首選治療。
"Colorectal cancer is the second leading cause of cancer death in Europe and patients are in need of new treatment options that delay disease progression. Approximately 5-7% of metastatic colorectal cancer patients have MSI-H/dMMR tumors and these patients are less likely to benefit from conventional chemotherapy and typically have poor prognosis outcomes," said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. "The EC's decision to approve Opdivo plus Yervoy represents a significant milestone for this patient population in the European Union and underscores our commitment to advancing treatment options."
"結直腸癌是歐洲第二大癌症死亡原因，患者需要新的治療選擇來延緩疾病進展。大約5-7%的轉移性結直腸癌患者有MSI-H/dMMR腫瘤，而這些患者從常規化療中獲益的可能性較小，通常預後較差，" 達納·沃克萬.D.萬.S.C.E.，百時美施貴寶Opdivo全球項目負責人、副總裁表示，"歐盟委員會批准Opdivo聯合Yervoy的決定對於這一患者群體來說是一個重要的里程碑，強調了我們致力於推進治療選擇的承諾。"
譯文內容由第三人軟體翻譯。
